WFA+ -M2BP appears to be a promising biomarker for NAFLD severity that will potentially help risk-stratify patients for enrollment in current clinical trials and could possibly replace liver biopsy in the future. This evidence concerns the gene LGALS3BP and metabolic dysfunction-associated steatotic liver disease.